Table 1 Prevalence of genitourinary cancer according to stage (localized/metastatic) and MDT impact on decision-making, patient’s adherence to MDT outcome
Type of Urological Cancer | Total, n (%) | Significant Impact, n (%) | Patient’s Adherence to MDTM outcome |
|---|---|---|---|
Prostate | 212(48.8) | 126(59.4) | 184(86.8) |
Localized | 120(56.6) | 77(64.2) | 109(90.8) |
Metastatic | 83(43.4) | 49(59.0) | 75(89.3) |
Renal cell | 107(24.6) | 71(66.3) | 95(88.8) |
Localized | 78(72.9) | 49(62.8) | 71(91.0) |
Metastatic | 29(27.1) | 22(75.8) | 24(82.8) |
Bladder Urothelial | 64(14.7) | 42(65.6) | 60(93.8) |
Localized | 53(86.9) | 35(66.0) | 53(100%) |
Metastatic | 11(13.1) | 7(63.6) | 7(63.6) |
Testis | 25(5.7) | 20(80.0) | 23(92) |
Localized | 10(40.0) | 8(80.0) | 10(100) |
Metastatic | 15(60.0) | 12(80.0) | 13(86.7) |
Upper Tract Urothelial | 23(5.3) | 17(73.9) | 20(87.0) |
Localized | 16(69.5) | 12(75) | 14(87.5) |
Metastatic | 7(30.5) | 5(71.4) | 6(85.7) |
Penile | 1(0.2) | 0(0) | 1(100) |
Localized | 1 | 0 | 1 |
Metastatic | 0 | 0 | 0 |
Total | 432(100) | 276(63.6) | 383(88.7) |